

SCDM 2024 Annual Conference

Festival of Opportunity

A decorative graphic in the bottom left corner consisting of a central point from which numerous thin, light blue lines radiate outwards. Some of these lines terminate in small, solid blue circles of varying sizes, creating a starburst or network-like effect.

Point of Failure: How Specialization is Preventing the Advancement of Clinical Data Management (CDM) and What We Can Do About It

Chaired by



Luke Gregory

Senior Director,
Clinical Data
Science
Systems (ICON
PLC)



Adri Erasmus

Senior Director,
Project Management
& Operations
(Bioforum)



**Mayank
Anand**

Global Vice
President (GSK)



Derek Lawrence

Senior Director,
Business
Enablement (Saama)

AI Adoption Barriers

"AI adoption is progressing more slowly than expected. Reported reasons include organizational lack of strategic planning, the customized requirements of each trial, the immaturity and fragmentation of commercially available AI-driven software, lack of scalability from pilots to enterprise adoption, and lack of addressing both process and organizational change. The lack of process change needed to implement AI solutions is being attributed to lack of leveraging of the technology to re-engineer clinical study processes, lack of organizational strategy and planning to move from pilots to enterprise adoption, and inability to measure success. Further, failure to change historic delineations of job roles and responsibilities is being cited as a significant factor inhibiting process re-engineering."

slido



Do you agree with this summary of the challenges facing CDM in terms of adopting new technologies?

① Start presenting to display the poll results on this slide.

slido



How novel do you feel are the challenges presented by AI & ML-driven technology adoption?

① Start presenting to display the poll results on this slide.

Plot Twist!

“EDC adoption progressed more slowly than the early surveys predicted. Reported reasons **included** organizational lack of strategic planning, the customized requirements of each trial, the immaturity and fragmentation of commercially available **EDC** software, lack of scalability from pilots to enterprise adoption, and lack of addressing both process and organizational change. The lack of process change needed to implement **EDC has been** attributed to lack of leveraging of the technology to re-engineer clinical study processes, lack of organizational strategy and planning to move from pilots to enterprise adoption, and inability to measure success. Further, failure to change historic delineations of job roles and responsibilities **has been** cited as a significant factor inhibiting process re-engineering.” ~ Zozus et al, JSCDM 2021

Panel Discussion: People & Skills

Panel Discussion: Process & Methodology

Panel Discussion: Moving Forward
